Polymer Drug Delivery Stabilization via Low pKa Acid Additives
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current polymer compositions for sustained drug release face challenges such as molecular weight reduction, peptide polymer impurities, and solubility issues, particularly with GnRH analogs, which affect their stability and usability in biological applications.
Innovation Solution
Incorporating a small amount of low pKa acids like lactic acid or glycolic acid into the polymer composition to prevent molecular weight reduction and adding an acid additive to maintain solubility and stability of GnRH analogs, thereby reducing impurities and gelling problems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polymer compositions are used for sustained drug release, then drug delivery effectiveness is improved, but molecular weight reduction and impurity formation occur
Solution Approach 1:
The patent introduces an intermediary substance (e.g., benzyl alcohol or other solvents) that mediates between the polymer and nucleophilic compounds. This intermediary prevents direct nucleophilic attack on the polymer ester bonds by creating a protective environment or competing reaction pathway, thereby maintaining molecular weight stability while preserving sustained drug release functionality.
Solution Approach 2:
The patent modifies chemical parameters by adjusting pH, adding acidifiers, or selecting specific polymer compositions with resistance to nucleophilic degradation. These parameter changes create conditions where the polymer remains stable despite the presence of nucleophilic drug compounds, resolving the contradiction between functionality and molecular weight stability.
2Reliability
If polymer compositions are used for sustained drug release, then drug delivery effectiveness is improved, but peptide polymer impurities are formed
Solution Approach 1:
The patent uses intermediary solvents or additives that prevent direct reaction between peptide drugs and polymer chains. This intermediary layer reduces the formation of peptide-polymer conjugates and impurities while maintaining the sustained release mechanism intact.
Solution Approach 2:
The patent creates an inert chemical environment by selecting solvents and conditions that minimize reactive interactions between peptide compounds and polymer esters. This inert environment prevents unwanted side reactions and impurity formation during formulation and storage.
3Reliability
If GnRH analogs are added to polymer composition, then therapeutic effectiveness is improved, but solubility issues and gelling occur
Solution Approach 1:
The patent adjusts solution parameters by adding acidifiers to lower pH, which increases the solubility of GnRH analogs and prevents gelling. This parameter modification maintains solution stability and homogeneity while preserving the therapeutic effectiveness of the GnRH analogs.
Solution Approach 2:
The patent introduces intermediary substances such as surfactants or co-solvents that act as mediators between GnRH analogs and the polymer matrix. These intermediaries improve solubility, prevent aggregation and gelling, while allowing the GnRH analogs to maintain their therapeutic activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively minimizes molecular weight reduction, eliminates peptide polymer impurities, and achieves stable, filter-sterilizable solutions of GnRH analogs, enhancing the reliability and regulatory compliance of polymer-based drug delivery systems.
Implementation Method 1
Incorporating a small amount of low pKa acids like lactic acid or glycolic acid into the polymer composition to prevent molecular weight reduction
Data Source
AI summary
Polymer and drug containing compositions and method of preparing such compositions are disclosed. The dispersed phase formulation has a polymer, a pharmaceutically or biologically active agent and a small fraction of low pKa acid additive. Stable, filter sterilizable, non-gelling solutions containing GnRH analogues at least at levels typically used in sustained release formulations and a method of increasing solubility of a high level of a GnRH analogue or a freeze-dried antagonist of GnRH in a polymer containing solution are also disclosed. The amount of the acid additive in the polymer solution is such that it is sufficient to increase the solubility of the high level of the GnRH analogue in the polymer solution without affecting the release characteristics of the microspheres prepared therefrom.